Pharmaceutical company Endo International (Nasdaq:ENDP) (TSX:ENDP) reported on Tuesday the start of delivery of the US Food and Drug Administration approved mycophenolate mofetil hydrochloride (HCl) for injection.
This shipment is being initiated by the company's operating company, Par Pharmaceutical.
The mycophenolate mofetil hydrochloride (HCl) for injection is the generic version of Roche's CellCept and is the first and currently the only generic injectable available. CellCept is a registered trademark of Hoffman-LaRoche Inc.
For the 12 months ended 31 October 2016, the US sales of injectable CellCept were about USD42m, according to IMS Health data.
Mycophenolate mofetil hydrochloride (HCl) for injection is packaged in cartons of four 500 mg single dose vials.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling